Physician profile
Maria E Szabela
NPI 1417379983
$474,160.84
in general payments reported to CMS, 2019-2025
12 companies · $139K in 2025
The $139K reported for 2025 was more than what 99% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $11K · 2021: $13K · 2022: $50K · 2023: $96K · 2024: $149K · 2025: $139K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $310K · Travel and Lodging: $49K · Consulting Fee: $15K · Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $309,922.50 |
| Travel and Lodging | $49,096.26 |
| Consulting Fee | $15,285.00 |
| Food and Beverage | $10,011.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $293,486.51 | 2019-2025 | Apretude, Cabenuva, Dovato |
| Gilead Sciences, INC. | $179,925.61 | 2019-2025 | Biktarvy, Descovy, Yeztugo |
| Janssen Products, Lp | $213.99 | 2019-2021 | |
| Theratechnologies INC. | $147.28 | 2019-2025 | Egrifta, Trogarzo |
| Janssen Biotech, INC. | $125.24 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $94.16 | 2019-2020 | |
| Kerecis Limited | $42.11 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Glaxosmithkline, LLC. | $35.70 | 2019-2022 | |
| Emd Serono, INC. | $30.00 | 2019 | |
| Allergan, INC. | $28.72 | 2019-2020 | |
| Abbvie INC. | $17.00 | 2023 | Mavyret |
| Napo Pharmaceuticals INC | $14.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Szabela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.